New perspectives in occult hepatitis C virus infection
Occult hepatitis C virus (HCV) infection, defined as the presence of HCV RNA in liver and in peripheral blood mononuclear cells (PBMCs) in the absence of detectable viral RNA in serum by standard assays, can be found in anti-HCV positive patients with normal serum levels of liver enzymes and in anti...
Saved in:
Published in | World journal of gastroenterology : WJG Vol. 18; no. 23; pp. 2887 - 2894 |
---|---|
Main Author | |
Format | Journal Article |
Language | English |
Published |
United States
Baishideng Publishing Group Co., Limited
21.06.2012
|
Subjects | |
Online Access | Get full text |
ISSN | 1007-9327 2219-2840 2219-2840 |
DOI | 10.3748/wjg.v18.i23.2887 |
Cover
Abstract | Occult hepatitis C virus (HCV) infection, defined as the presence of HCV RNA in liver and in peripheral blood mononuclear cells (PBMCs) in the absence of detectable viral RNA in serum by standard assays, can be found in anti-HCV positive patients with normal serum levels of liver enzymes and in anti-HCV negative patients with persistently elevated liver enzymes of unknown etiology. Occult HCV infection is distributed worldwide and all HCV genotypes seem to be involved in this infection. Occult hepatitis C has been found not only in anti-HCV positive subjects with normal values of liver enzymes or in chronic hepatitis of unknown origin but also in several groups at risk for HCV infection such as hemodialysis patients or family members of patients with occult HCV. This occult infection has been reported also in healthy populations without evidence of liver disease. Occult HCV infection seems to be less aggressive than chronic hepatitis C although patients affected by occult HCV may develop liver cirrhosis and even hepatocellular carcinoma. Thus, anti-HCV negative patients with occult HCV may benefit from antiviral therapy with pegylated-interferon plus ribavirin. The persistence of very low levels of HCV RNA in serum and in PBMCs, along with the maintenance of specific T-cell responses against HCV-antigens observed during a long-term follow-up of patients with occult hepatitis C, indicate that occult HCV is a persistent infection that is not spontaneously eradicated. This is an updated report on diagnosis, epidemiology and clinical implications of occult HCV with special emphasis on anti-HCV negative cases. |
---|---|
AbstractList | Occult hepatitis C virus (HCV) infection, defined as the presence of HCV RNA in liver and in peripheral blood mononuclear cells (PBMCs) in the absence of detectable viral RNA in serum by standard assays, can be found in anti-HCV positive patients with normal serum levels of liver enzymes and in anti-HCV negative patients with persistently elevated liver enzymes of unknown etiology. Occult HCV infection is distributed worldwide and all HCV genotypes seem to be involved in this infection. Occult hepatitis C has been found not only in anti-HCV positive subjects with normal values of liver enzymes or in chronic hepatitis of unknown origin but also in several groups at risk for HCV infection such as hemodialysis patients or family members of patients with occult HCV. This occult infection has been reported also in healthy populations without evidence of liver disease. Occult HCV infection seems to be less aggressive than chronic hepatitis C although patients affected by occult HCV may develop liver cirrhosis and even hepatocellular carcinoma. Thus, anti-HCV negative patients with occult HCV may benefit from antiviral therapy with pegylated-interferon plus ribavirin. The persistence of very low levels of HCV RNA in serum and in PBMCs, along with the maintenance of specific T-cell responses against HCV-antigens observed during a long-term follow-up of patients with occult hepatitis C, indicate that occult HCV is a persistent infection that is not spontaneously eradicated. This is an updated report on diagnosis, epidemiology and clinical implications of occult HCV with special emphasis on anti-HCV negative cases. Occult hepatitis C virus (HCV) infection, defined as the presence of HCV RNA in liver and in peripheral blood mononuclear cells (PBMCs) in the absence of detectable viral RNA in serum by standard assays, can be found in anti-HCV positive patients with normal serum levels of liver enzymes and in anti-HCV negative patients with persistently elevated liver enzymes of unknown etiology. Occult HCV infection is distributed worldwide and all HCV genotypes seem to be involved in this infection. Occult hepatitis C has been found not only in anti-HCV positive subjects with normal values of liver enzymes or in chronic hepatitis of unknown origin but also in several groups at risk for HCV infection such as hemodialysis patients or family members of patients with occult HCV. This occult infection has been reported also in healthy populations without evidence of liver disease. Occult HCV infection seems to be less aggressive than chronic hepatitis C although patients affected by occult HCV may develop liver cirrhosis and even hepatocellular carcinoma. Thus, anti-HCV negative patients with occult HCV may benefit from antiviral therapy with pegylated-interferon plus ribavirin. The persistence of very low levels of HCV RNA in serum and in PBMCs, along with the maintenance of specific T-cell responses against HCV-antigens observed during a long-term follow-up of patients with occult hepatitis C, indicate that occult HCV is a persistent infection that is not spontaneously eradicated. This is an updated report on diagnosis, epidemiology and clinical implications of occult HCV with special emphasis on anti-HCV negative cases. Occult hepatitis C virus (HCV) infection, defined as the presence of HCV RNA in liver and in peripheral blood mononuclear cells (PBMCs) in the absence of detectable viral RNA in serum by standard assays, can be found in anti-HCV positive patients with normal serum levels of liver enzymes and in anti-HCV negative patients with persistently elevated liver enzymes of unknown etiology. Occult HCV infection is distributed worldwide and all HCV genotypes seem to be involved in this infection. Occult hepatitis C has been found not only in anti-HCV positive subjects with normal values of liver enzymes or in chronic hepatitis of unknown origin but also in several groups at risk for HCV infection such as hemodialysis patients or family members of patients with occult HCV. This occult infection has been reported also in healthy populations without evidence of liver disease. Occult HCV infection seems to be less aggressive than chronic hepatitis C although patients affected by occult HCV may develop liver cirrhosis and even hepatocellular carcinoma. Thus, anti-HCV negative patients with occult HCV may benefit from antiviral therapy with pegylated-interferon plus ribavirin. The persistence of very low levels of HCV RNA in serum and in PBMCs, along with the maintenance of specific T-cell responses against HCV-antigens observed during a long-term follow-up of patients with occult hepatitis C, indicate that occult HCV is a persistent infection that is not spontaneously eradicated. This is an updated report on diagnosis, epidemiology and clinical implications of occult HCV with special emphasis on anti-HCV negative cases.Occult hepatitis C virus (HCV) infection, defined as the presence of HCV RNA in liver and in peripheral blood mononuclear cells (PBMCs) in the absence of detectable viral RNA in serum by standard assays, can be found in anti-HCV positive patients with normal serum levels of liver enzymes and in anti-HCV negative patients with persistently elevated liver enzymes of unknown etiology. Occult HCV infection is distributed worldwide and all HCV genotypes seem to be involved in this infection. Occult hepatitis C has been found not only in anti-HCV positive subjects with normal values of liver enzymes or in chronic hepatitis of unknown origin but also in several groups at risk for HCV infection such as hemodialysis patients or family members of patients with occult HCV. This occult infection has been reported also in healthy populations without evidence of liver disease. Occult HCV infection seems to be less aggressive than chronic hepatitis C although patients affected by occult HCV may develop liver cirrhosis and even hepatocellular carcinoma. Thus, anti-HCV negative patients with occult HCV may benefit from antiviral therapy with pegylated-interferon plus ribavirin. The persistence of very low levels of HCV RNA in serum and in PBMCs, along with the maintenance of specific T-cell responses against HCV-antigens observed during a long-term follow-up of patients with occult hepatitis C, indicate that occult HCV is a persistent infection that is not spontaneously eradicated. This is an updated report on diagnosis, epidemiology and clinical implications of occult HCV with special emphasis on anti-HCV negative cases. |
Author | Vicente Carreno Javier Bartolome Inmaculada Castillo Juan Antonio Quiroga |
AuthorAffiliation | Foundation for the Study of Viral Hepa-titis, C/Guzman el Bueno 72, 28015 Madrid, Spain |
Author_xml | – sequence: 1 fullname: Vicente Carreno Javier Bartolome Inmaculada Castillo Juan Antonio Quiroga |
BackLink | https://www.ncbi.nlm.nih.gov/pubmed/22736911$$D View this record in MEDLINE/PubMed |
BookMark | eNp9kTFv2zAQhYkiReMk3TMF6tZFLu8oieRSoDDaJEDQLu1MUPTJZiCTiig56L-PhDhG0yHTDfe99w73zthJiIEYuwS-FLJQXx7vN8s9qKVHsUSl5Du2QASdoyr4CVsA5zLXAuUpO0vpnnMUosQP7BRRikoDLFj1kx6zjvrUkRv8nlLmQxadG9sh21JnBz_4lK2yve_HedfMWAwX7H1j20QfD_Oc_fnx_ffqJr_7dX27-naXuyloyAVQU9VNralEQisbgFprK20zX2CtVriWuK5RFrVSAK5CkLTWKEoNBRTinH199u3GekdrR2HobWu63u9s_9dE683rTfBbs4l7I4TiAsrJ4PPBoI8PI6XB7Hxy1LY2UByTAY5YlprzGb36N-sY8vKsCeDPgOtjSj01RwS4mfswUx9m6sNMfZi5j0lS_SdxfrDzB6drffuW8NNBuI1h8-DD5hhWYMk1lJV4AhTmnG0 |
CitedBy_id | crossref_primary_10_1007_s00005_015_0364_8 crossref_primary_10_6002_ect_2017_0332 crossref_primary_10_1007_s00705_018_4066_5 crossref_primary_10_1111_trf_13127 crossref_primary_10_1111_liv_12320 crossref_primary_10_1007_s00005_013_0257_7 crossref_primary_10_1111_jvh_12526 crossref_primary_10_5812_jjm_8_4_2015_17157 crossref_primary_10_1007_s11356_017_0897_y crossref_primary_10_1016_j_jiph_2022_11_008 crossref_primary_10_5812_ircmj_34181 crossref_primary_10_1007_s10096_013_1857_1 crossref_primary_10_1002_jmv_25279 crossref_primary_10_5812_hepatmon_16089 crossref_primary_10_4254_wjh_v13_i2_242 crossref_primary_10_1016_j_meegid_2019_104144 crossref_primary_10_1097_CAD_0b013e32835ec39a crossref_primary_10_1002_jmv_24467 crossref_primary_10_1111_hepr_13325 crossref_primary_10_1002_jmv_24074 crossref_primary_10_1007_s00705_018_3922_7 crossref_primary_10_1007_s00705_016_3049_7 crossref_primary_10_1177_039463201402700111 crossref_primary_10_1186_1471_2334_12_S2_S2 crossref_primary_10_1371_journal_pone_0205659 crossref_primary_10_15406_ppij_2023_11_00394 crossref_primary_10_1111_vox_12547 crossref_primary_10_1002_jmv_25808 crossref_primary_10_5812_jjm_121929 crossref_primary_10_1111_vox_12301 crossref_primary_10_1177_2058738420961202 crossref_primary_10_4254_wjh_v6_i6_419 crossref_primary_10_1007_s12288_018_0968_3 crossref_primary_10_1155_2015_579147 crossref_primary_10_1002_jmv_25769 crossref_primary_10_18821_0507_4088_2019_64_1_30_35 crossref_primary_10_1002_hep_27626 crossref_primary_10_29252_JoMMID_8_1_1 crossref_primary_10_1007_s10238_022_00791_7 crossref_primary_10_1007_s00705_016_2862_3 crossref_primary_10_3748_wjg_v21_i38_10790 crossref_primary_10_2174_1568026619666190510094228 crossref_primary_10_5812_hepatmon_16665 crossref_primary_10_1016_j_ajg_2018_09_001 crossref_primary_10_5812_hepatmon_11290 crossref_primary_10_1159_000455854 crossref_primary_10_1007_s00431_014_2286_6 crossref_primary_10_1080_00365521_2020_1790649 crossref_primary_10_21320_2500_2139_2023_16_1_46_53 crossref_primary_10_1016_j_ajg_2021_03_001 crossref_primary_10_1158_1055_9965_EPI_13_0397 crossref_primary_10_3748_wjg_v24_i20_2191 crossref_primary_10_4292_wjgpt_v7_i1_33 crossref_primary_10_1007_s13337_024_00881_y crossref_primary_10_34172_mejdd_2022_275 crossref_primary_10_5662_wjm_v12_i3_179 crossref_primary_10_7314_APJCP_2012_13_12_5917 crossref_primary_10_4254_wjh_v9_i33_1239 |
ContentType | Journal Article |
Copyright | 2012 Baishideng Publishing Group Co., Limited. All rights reserved. 2012 |
Copyright_xml | – notice: 2012 Baishideng Publishing Group Co., Limited. All rights reserved. 2012 |
DBID | 2RA 92L CQIGP W91 ~WA AAYXX CITATION CGR CUY CVF ECM EIF NPM 7X8 5PM |
DOI | 10.3748/wjg.v18.i23.2887 |
DatabaseName | 维普期刊资源整合服务平台 中文科技期刊数据库-CALIS站点 中文科技期刊数据库-7.0平台 中文科技期刊数据库-医药卫生 中文科技期刊数据库- 镜像站点 CrossRef Medline MEDLINE MEDLINE (Ovid) MEDLINE MEDLINE PubMed MEDLINE - Academic PubMed Central (Full Participant titles) |
DatabaseTitle | CrossRef MEDLINE Medline Complete MEDLINE with Full Text PubMed MEDLINE (Ovid) MEDLINE - Academic |
DatabaseTitleList | MEDLINE MEDLINE - Academic |
Database_xml | – sequence: 1 dbid: NPM name: PubMed url: https://proxy.k.utb.cz/login?url=http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=PubMed sourceTypes: Index Database – sequence: 2 dbid: EIF name: MEDLINE url: https://proxy.k.utb.cz/login?url=https://www.webofscience.com/wos/medline/basic-search sourceTypes: Index Database |
DeliveryMethod | fulltext_linktorsrc |
DocumentTitleAlternate | New perspectives in occult hepatitis C virus infection |
EISSN | 2219-2840 |
EndPage | 2894 |
ExternalDocumentID | PMC3380315 22736911 10_3748_wjg_v18_i23_2887 42509156 |
Genre | Research Support, Non-U.S. Gov't Editorial |
GroupedDBID | --- 123 29R 2B. 2C~ 2RA 2WC 36B 53G 5VR 8WL 92F 92I 92L 93N 93R AAKDD ACGFO AENEX AFUIB ALMA_UNASSIGNED_HOLDINGS CCEZO CHBEP CIEJG CQIGP CS3 CW9 DIK DU5 E3Z EBS EJD EMB F5P FA0 FRP GX1 HYE M~E OK1 P2P RNS RPM SV3 TCJ TGQ TR2 W91 WFFXF XSB ~WA AAYXX CITATION CGR CUY CVF ECM EIF NPM 7X8 5PM |
ID | FETCH-LOGICAL-c352t-31ef6bfb9e52e2a7f11b99a7af2273aa982d72db274b8811c6217ed9235914143 |
ISSN | 1007-9327 2219-2840 |
IngestDate | Thu Aug 21 13:34:38 EDT 2025 Fri Jul 11 00:06:00 EDT 2025 Mon Jul 21 05:52:26 EDT 2025 Tue Jul 01 03:21:55 EDT 2025 Thu Apr 24 23:05:30 EDT 2025 Wed Feb 14 10:46:24 EST 2024 |
IsDoiOpenAccess | false |
IsOpenAccess | true |
IsPeerReviewed | false |
IsScholarly | true |
Issue | 23 |
Keywords | Peripheral blood mononuclear cells Hepatitis C virus RNA Occult hepatitis C virus Liver T-cell response |
Language | English |
LinkModel | OpenURL |
MergedId | FETCHMERGED-LOGICAL-c352t-31ef6bfb9e52e2a7f11b99a7af2273aa982d72db274b8811c6217ed9235914143 |
Notes | Occult hepatitis C virus (HCV) infection, defined as the presence of HCV RNA in liver and in peripheral blood mononuclear cells (PBMCs) in the absence of detectable viral RNA in serum by standard assays, can be found in anti-HCV positive patients with normal serum levels of liver enzymes and in anti-HCV negative patients with persistently elevated liver enzymes of unknown etiology. Occult HCV infection is distributed worldwide and all HCV genotypes seem to be involved in this infection. Occult hepatitis C has been found not only in anti-HCV positive subjects with normal values of liver enzymes or in chronic hepatitis of unknown origin but also in several groups at risk for HCV infection such as hemodialysis patients or family members of patients with occult HCV. This occult infection has been reported also in healthy populations without evidence of liver disease. Occult HCV infection seems to be less aggressive than chronic hepatitis C although patients affected by occult HCV may develop liver cirrhosis and even hepatocellular carcinoma. Thus, anti-HCV negative patients with occult HCV may benefit from antiviral therapy with pegylated-interferon plus ribavirin. The persistence of very low levels of HCV RNA in serum and in PBMCs, along with the maintenance of specific T-cell responses against HCV-antigens observed during a long-term follow-up of patients with occult hepatitis C, indicate that occult HCV is a persistent infection that is not spontaneously eradicated. This is an updated report on diagnosis, epidemiology and clinical implications of occult HCV with special emphasis on anti-HCV negative cases. 14-1219/R Occult hepatitis C virus; Hepatitis C virusRNA; Liver; Peripheral blood mononuclear cells; T-cellresponse SourceType-Scholarly Journals-1 content type line 23 ObjectType-Editorial-2 ObjectType-Commentary-1 ObjectType-Article-3 Author contributions: Carreño V, Bartolomé J, Castillo I and Quiroga JA equally contributed to generating the ideas for this review and writing this manuscript. Correspondence to: Vicente Carreño, MD, PhD, Foundation for the Study of Viral Hepatitis, C/Guzmán el Bueno 72, 28015 Madrid, Spain. fehvhpa@fehv.org Telephone: +34-91-5446013 Fax: +34-91-5449228 |
OpenAccessLink | https://www.wjgnet.com/1007-9327/full/v18/i23/2887.htm |
PMID | 22736911 |
PQID | 1022559005 |
PQPubID | 23479 |
PageCount | 8 |
ParticipantIDs | pubmedcentral_primary_oai_pubmedcentral_nih_gov_3380315 proquest_miscellaneous_1022559005 pubmed_primary_22736911 crossref_primary_10_3748_wjg_v18_i23_2887 crossref_citationtrail_10_3748_wjg_v18_i23_2887 chongqing_primary_42509156 |
ProviderPackageCode | CITATION AAYXX |
PublicationCentury | 2000 |
PublicationDate | 2012-06-21 |
PublicationDateYYYYMMDD | 2012-06-21 |
PublicationDate_xml | – month: 06 year: 2012 text: 2012-06-21 day: 21 |
PublicationDecade | 2010 |
PublicationPlace | United States |
PublicationPlace_xml | – name: United States |
PublicationTitle | World journal of gastroenterology : WJG |
PublicationTitleAlternate | World Journal of Gastroenterology |
PublicationYear | 2012 |
Publisher | Baishideng Publishing Group Co., Limited |
Publisher_xml | – name: Baishideng Publishing Group Co., Limited |
References | 16323211 - Hepatology. 2006 Jan;43(1):91-9 11055514 - Curr Opin Hematol. 2000 Nov;7(6):397-401 16611276 - Aliment Pharmacol Ther. 2006 Apr 15;23(8):1153-9 10365827 - J Hepatol. 1999 May;30(5):956-61 16537674 - J Clin Pathol. 2006 May;59(5):526-9 21699630 - J Viral Hepat. 2012 Feb;19(2):103-11 17181568 - Eur J Clin Invest. 2007 Jan;37(1):54-64 18712814 - J Med Virol. 2008 Oct;80(10):1720-2 18505381 - J Infect Dis. 2008 Jul 15;198(2):203-12 15140984 - J Virol. 2004 Jun;78(11):5867-74 15736006 - Clin Infect Dis. 2005 Mar 15;40(6):e49-54 19523175 - Aliment Pharmacol Ther. 2009 Sep 1;30(5):477-86 20960374 - Semin Liver Dis. 2010 Nov;30(4):333-47 20648609 - J Med Virol. 2010 Sep;82(9):1554-9 14518724 - J Biol Regul Homeost Agents. 2003 Apr-Jun;17(2):198-204 9620345 - Hepatology. 1998 Jun;27(6):1700-2 15619235 - Hepatology. 2005 Jan;41(1):106-14 18647233 - J Viral Hepat. 2009 Jan;16(1):10-20 11583749 - Lancet. 2001 Sep 22;358(9286):958-65 17021056 - J Clin Microbiol. 2006 Dec;44(12):4559-60 20070513 - Liver Int. 2010 Apr;30(4):502-11 15964345 - Transplant Proc. 2005 Jun;37(5):2083-5 21184846 - Infect Genet Evol. 2011 Mar;11(2):442-5 7597443 - Semin Liver Dis. 1995 Feb;15(1):41-63 9403936 - Res Virol. 1997 Sep-Oct;148(5):367-73 10859368 - J Gen Virol. 2000 Jul;81(Pt 7):1631-48 22093326 - Liver Int. 2011 Nov;31(10):1519-24 15319859 - J Infect Dis. 2004 Sep 15;190(6):1093-7 17475654 - J Virol. 2007 Jul;81(14):7710-5 15838801 - J Infect Dis. 2005 May 15;191(10):1730-3 12107020 - Lancet Oncol. 2002 Jun;3(6):333-40 17071928 - J Virol. 2006 Nov;80(22):10972-9 21205133 - Liver Int. 2011 Jan;31 Suppl 1:18-22 15122521 - J Infect Dis. 2004 May 15;189(10):1846-55 15664228 - Lancet. 2005 Jan 22-28;365(9456):327-9 15831916 - Gut. 2005 May;54(5):682-5 18265423 - Rev Med Virol. 2008 May-Jun;18(3):139-57 16474148 - J Virol. 2006 Mar;80(5):2418-28 16741882 - J Infect Dis. 2006 Jul 1;194(1):53-60 15589744 - Transpl Immunol. 2004 Dec;13(4):305-11 17051492 - Clin Infect Dis. 2006 Nov 15;43(10):1277-83 19215578 - J Viral Hepat. 2009 Aug;16(8):547-56 14635013 - J Med Virol. 2004 Jan;72(1):66-74 10802716 - Nat Med. 2000 May;6(5):578-82 16847959 - J Med Virol. 2006 Sep;78(9):1190-7 9807989 - Lancet. 1998 Oct 31;352(9138):1426-32 21503911 - J Med Virol. 2011 Jun;83(6):989-95 14702147 - J Infect Dis. 2004 Jan 1;189(1):7-14 19956542 - PLoS One. 2009;4(12):e8128 19475603 - J Med Virol. 2009 Jul;81(7):1198-203 20380524 - Immunol Invest. 2010 Jan;39(3):284-91 15168768 - Intern Med. 2004 Apr;43(4):279-82 16406797 - J Clin Virol. 2006 Apr;35(4):368-72 16107964 - J Infect Dis. 2005 Sep 15;192(6):1088-92 15191008 - Clin Oncol (R Coll Radiol). 2004 May;16(3):204-5 19330875 - Hepatology. 2009 Apr;49(4):1335-74 17650287 - J Viral Hepat. 2007 Aug;14(8):537-48 19070391 - J Hepatol. 2009 Feb;50(2):256-63 16122679 - Lancet Infect Dis. 2005 Sep;5(9):558-67 8058787 - Proc Natl Acad Sci U S A. 1994 Aug 16;91(17):8239-43 20345213 - Crit Rev Microbiol. 2010 May;36(2):91-133 18684893 - J Am Soc Nephrol. 2008 Dec;19(12):2288-92 10622555 - J Hepatol. 1999;31 Suppl 1:17-24 16569433 - J Infect. 2007 Feb;54(2):173-9 17212642 - J Viral Hepat. 2007 Jan;14(1):36-40 21040725 - Gastroenterology. 2011 Feb;140(2):676-685.e1 |
References_xml | – reference: 16847959 - J Med Virol. 2006 Sep;78(9):1190-7 – reference: 20648609 - J Med Virol. 2010 Sep;82(9):1554-9 – reference: 15191008 - Clin Oncol (R Coll Radiol). 2004 May;16(3):204-5 – reference: 17181568 - Eur J Clin Invest. 2007 Jan;37(1):54-64 – reference: 19330875 - Hepatology. 2009 Apr;49(4):1335-74 – reference: 17021056 - J Clin Microbiol. 2006 Dec;44(12):4559-60 – reference: 18505381 - J Infect Dis. 2008 Jul 15;198(2):203-12 – reference: 17650287 - J Viral Hepat. 2007 Aug;14(8):537-48 – reference: 20345213 - Crit Rev Microbiol. 2010 May;36(2):91-133 – reference: 17051492 - Clin Infect Dis. 2006 Nov 15;43(10):1277-83 – reference: 15664228 - Lancet. 2005 Jan 22-28;365(9456):327-9 – reference: 16537674 - J Clin Pathol. 2006 May;59(5):526-9 – reference: 17071928 - J Virol. 2006 Nov;80(22):10972-9 – reference: 11055514 - Curr Opin Hematol. 2000 Nov;7(6):397-401 – reference: 21040725 - Gastroenterology. 2011 Feb;140(2):676-685.e1 – reference: 15619235 - Hepatology. 2005 Jan;41(1):106-14 – reference: 15964345 - Transplant Proc. 2005 Jun;37(5):2083-5 – reference: 10365827 - J Hepatol. 1999 May;30(5):956-61 – reference: 10622555 - J Hepatol. 1999;31 Suppl 1:17-24 – reference: 8058787 - Proc Natl Acad Sci U S A. 1994 Aug 16;91(17):8239-43 – reference: 12107020 - Lancet Oncol. 2002 Jun;3(6):333-40 – reference: 19070391 - J Hepatol. 2009 Feb;50(2):256-63 – reference: 15140984 - J Virol. 2004 Jun;78(11):5867-74 – reference: 16611276 - Aliment Pharmacol Ther. 2006 Apr 15;23(8):1153-9 – reference: 14518724 - J Biol Regul Homeost Agents. 2003 Apr-Jun;17(2):198-204 – reference: 16107964 - J Infect Dis. 2005 Sep 15;192(6):1088-92 – reference: 21699630 - J Viral Hepat. 2012 Feb;19(2):103-11 – reference: 21184846 - Infect Genet Evol. 2011 Mar;11(2):442-5 – reference: 16474148 - J Virol. 2006 Mar;80(5):2418-28 – reference: 15831916 - Gut. 2005 May;54(5):682-5 – reference: 14635013 - J Med Virol. 2004 Jan;72(1):66-74 – reference: 9807989 - Lancet. 1998 Oct 31;352(9138):1426-32 – reference: 16323211 - Hepatology. 2006 Jan;43(1):91-9 – reference: 19215578 - J Viral Hepat. 2009 Aug;16(8):547-56 – reference: 21503911 - J Med Virol. 2011 Jun;83(6):989-95 – reference: 14702147 - J Infect Dis. 2004 Jan 1;189(1):7-14 – reference: 9620345 - Hepatology. 1998 Jun;27(6):1700-2 – reference: 20960374 - Semin Liver Dis. 2010 Nov;30(4):333-47 – reference: 16122679 - Lancet Infect Dis. 2005 Sep;5(9):558-67 – reference: 17475654 - J Virol. 2007 Jul;81(14):7710-5 – reference: 15838801 - J Infect Dis. 2005 May 15;191(10):1730-3 – reference: 18265423 - Rev Med Virol. 2008 May-Jun;18(3):139-57 – reference: 15168768 - Intern Med. 2004 Apr;43(4):279-82 – reference: 16406797 - J Clin Virol. 2006 Apr;35(4):368-72 – reference: 19523175 - Aliment Pharmacol Ther. 2009 Sep 1;30(5):477-86 – reference: 21205133 - Liver Int. 2011 Jan;31 Suppl 1:18-22 – reference: 22093326 - Liver Int. 2011 Nov;31(10):1519-24 – reference: 15736006 - Clin Infect Dis. 2005 Mar 15;40(6):e49-54 – reference: 10859368 - J Gen Virol. 2000 Jul;81(Pt 7):1631-48 – reference: 18684893 - J Am Soc Nephrol. 2008 Dec;19(12):2288-92 – reference: 18712814 - J Med Virol. 2008 Oct;80(10):1720-2 – reference: 15319859 - J Infect Dis. 2004 Sep 15;190(6):1093-7 – reference: 17212642 - J Viral Hepat. 2007 Jan;14(1):36-40 – reference: 20070513 - Liver Int. 2010 Apr;30(4):502-11 – reference: 15122521 - J Infect Dis. 2004 May 15;189(10):1846-55 – reference: 7597443 - Semin Liver Dis. 1995 Feb;15(1):41-63 – reference: 16741882 - J Infect Dis. 2006 Jul 1;194(1):53-60 – reference: 19475603 - J Med Virol. 2009 Jul;81(7):1198-203 – reference: 11583749 - Lancet. 2001 Sep 22;358(9286):958-65 – reference: 20380524 - Immunol Invest. 2010 Jan;39(3):284-91 – reference: 19956542 - PLoS One. 2009;4(12):e8128 – reference: 15589744 - Transpl Immunol. 2004 Dec;13(4):305-11 – reference: 9403936 - Res Virol. 1997 Sep-Oct;148(5):367-73 – reference: 16569433 - J Infect. 2007 Feb;54(2):173-9 – reference: 10802716 - Nat Med. 2000 May;6(5):578-82 – reference: 18647233 - J Viral Hepat. 2009 Jan;16(1):10-20 |
SSID | ssj0023352 |
Score | 2.2846944 |
Snippet | Occult hepatitis C virus (HCV) infection, defined as the presence of HCV RNA in liver and in peripheral blood mononuclear cells (PBMCs) in the absence of... Occult hepatitis C virus (HCV) infection, defined as the presence of HCV RNA in liver and in peripheral blood mononuclear cells (PBMCs) in the absence of... |
SourceID | pubmedcentral proquest pubmed crossref chongqing |
SourceType | Open Access Repository Aggregation Database Index Database Enrichment Source Publisher |
StartPage | 2887 |
SubjectTerms | Antiviral Agents - therapeutic use Asymptomatic Infections Hepacivirus - genetics Hepatitis C - diagnosis Hepatitis C - drug therapy Hepatitis C - immunology Humans Leukocytes, Mononuclear - chemistry Liver - chemistry RNA, Viral - analysis Serologic Tests T细胞反应 丙型肝炎病毒 外周血单个核细胞 抗原特异性 抗病毒治疗 病毒感染 肝脏疾病 隐匿性 |
Title | New perspectives in occult hepatitis C virus infection |
URI | http://lib.cqvip.com/qk/84123X/201223/42509156.html https://www.ncbi.nlm.nih.gov/pubmed/22736911 https://www.proquest.com/docview/1022559005 https://pubmed.ncbi.nlm.nih.gov/PMC3380315 |
Volume | 18 |
hasFullText | 1 |
inHoldings | 1 |
isFullTextHit | |
isPrint | |
link | http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwnV3Nb9MwFLdgXLigTXxlAxQkLmhK1ziJ7RxZBZomwWmD3SzbcboglIw23aT99bxnJ2laNolxiarUfXL8S59_7_l9EPLB-TYKbiJh0iRKmbGRorSMppYLBe9zzDjmO3_9xk7O09OL7GLd7c1ll7R6Ym7vzCv5H1ThHuCKWbIPQHYQCjfgM-ALV0AYrv-EMQYnXq2zJV1oa2OwmAYQQAyVbqvl4ezwulqs1mFX9ZiP-liaUfmIuVq2iwYLdS58dSZ0Gfw4HTpwzTC0F0_Xj2PnZP1eYXinHTsPMAqDRT4judN36KkECsfvVoirPhu4V2_C747behdr2MBi3fycT65jMaloMumHbpa43tp6hoBAMEVQhgQJYLYLCRIkSnhMnlDO3fm7c8N0ljQmirlj7G72_vwZJRxtzwFrZlw29fw3MIFN7vGXQbEdFzsiGme75FlnIYSfPNx75JGtnxMGUIdjqMOqDj3U4QB1OAsd1OEA9Qty_uXz2ewk6lpeRAYeqYUd0ZZMlzq3GbVU8TKOdZ4rrkoKPFOpXNCC00JTnmoh4tgwMCltASw9y-MUuO9LslM3tX1NQpExU5gysUjhLBWawrgkzXmip3aamYDsDwsjr3xpEwkaHAhkxgJy1K-UNF2xeOxZ8kveh1RAPg6_6KXdP_Z9v_gStBkeUanaNqulRP9Dho1ss4C88mAM0nAFGOzNAeEbMA0DsFL65jd1dekqpieJwG4m-w-Y4wF5uv7DvCE77WJl3wL_bPU79y7-AbKZhlM |
linkProvider | National Library of Medicine |
openUrl | ctx_ver=Z39.88-2004&ctx_enc=info%3Aofi%2Fenc%3AUTF-8&rfr_id=info%3Asid%2Fsummon.serialssolutions.com&rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal&rft.genre=article&rft.atitle=New+perspectives+in+occult+hepatitis+C+virus+infection&rft.jtitle=World+journal+of+gastroenterology+%3A+WJG&rft.au=Carre%C3%B1o%2C+Vicente&rft.date=2012-06-21&rft.issn=1007-9327&rft.volume=18&rft.issue=23&rft.spage=2887&rft_id=info:doi/10.3748%2Fwjg.v18.i23.2887&rft.externalDBID=n%2Fa&rft.externalDocID=10_3748_wjg_v18_i23_2887 |
thumbnail_s | http://utb.summon.serialssolutions.com/2.0.0/image/custom?url=http%3A%2F%2Fimage.cqvip.com%2Fvip1000%2Fqk%2F84123X%2F84123X.jpg |